Obefazimod Phase 3 and Long-Term Ulcerative Colitis Data to Debut at UEG Week 2026
New data on obefazimod for ulcerative colitis will be shared at a major GI meeting
If you or someone you care for has ulcerative colitis (UC), you may be following news about new medicines. UC is a long-term condition that causes inflammation and ulcers in the large intestine, often leading to symptoms such as frequent diarrhea, blood in the stool, bowel urgency, and disturbed sleep from nighttime toilet trips.
This October, researchers will present new clinical and laboratory findings about an investigational drug called obefazimod (ABX464) at United European Gastroenterology (UEG) Week 2026, held October 17–20 in Barcelona, Spain (Source: United European Gastroenterology Week 2026).
What is obefazimod?
Obefazimod is an experimental treatment currently being tested in people with moderately to severely active UC. It is still in clinical trials, which means it is not yet approved for general use and doctors do not routinely prescribe it outside of studies.
What will be presented at the meeting?
The conference program will feature seven presentations about obefazimod: four oral talks and three posters. These cover results from late-stage (phase 3) trials, longer-term follow-up from earlier (phase 2) work, and lab studies that look at how the drug may affect inflammation, scarring (fibrosis), and tumor growth in animal models.
Phase 3 maintenance trial
One of the main items is the 44-week, randomized, double-blind, placebo-controlled phase 3 trial called ABTECT-Maintenance. That description means patients were assigned by chance to take either obefazimod or a dummy pill, neither study participants nor researchers knew who had which pill, and results after 44 weeks will be compared between groups. Results from this trial will be presented during the Hot Topics in Clinical GI Research session on October 19 by Steven Sands, MD (Source: United European Gastroenterology Week 2026).
How prior treatment history may matter
Another presentation will look at how patients’ previous experience with advanced therapies (for example, biologics or other newer drugs) relates to how well obefazimod worked when used for 44 weeks. That analysis will be shared by Silvio Danese, MD, PhD, and it compares outcomes for people who did or did not have an inadequate response to prior advanced treatment (Source: United European Gastroenterology Week 2026).
Long-term phase 2 findings
Researchers will also report longer-term data from the phase 2 program. An oral presentation will give a 3-year interim look at how well patients did and whether they stayed on treatment after their dose was reduced to 25 mg and they reached week 144. The analysis will break results down by whether patients had previously received advanced therapies.
A related moderated poster will cover the same topics—efficacy, persistence (how long people stayed on the drug), and safety—through three years after dose reduction in the open-label phase 2 maintenance study (Source: United European Gastroenterology Week 2026).
Patient-reported symptoms
Beyond lab tests and clinical scores, patients’ day-to-day symptoms matter a lot. Pooled data from the two 8-week ABTECT phase 3 induction trials will look at whether improvements in bowel urgency and nighttime bowel movements are linked with better clinical outcomes for people treated with obefazimod. This analysis will be presented as a moderated poster on October 18 by William J. Rubin, MD (Source: United European Gastroenterology Week 2026).
Preclinical work: inflammation, fibrosis, and tumor models
Some talks will show laboratory and animal research to explore how obefazimod may work. Presentations include studies of the drug’s effects on microRNA-124 (miR-124), a small molecule that helps control inflammation, and experiments looking at inflammation-driven fibrosis and tumor burden in a mouse model of colitis-associated cancer.
It’s important to note that these are preclinical findings in animals or lab models, which do not prove that obefazimod will have the same anticancer or anti-fibrosis effects in people (Source: United European Gastroenterology Week 2026).
What this means for patients
These presentations will add more information about obefazimod’s effects during initial treatment (induction), over longer maintenance periods, and after cutting the dose. The data include randomized phase 3 results, long-term follow-up from phase 2, and laboratory studies that try to explain how the drug works.
Because the drug is still investigational, we can’t say it is safe and effective for routine use yet. Results presented at a conference are an early step—researchers typically publish the full studies later in medical journals and regulatory agencies review the total evidence before any approval decisions. If you are considering new treatments, talk with your gastroenterologist to understand what the latest research may or may not mean for you.
When to see a doctor
See your gastroenterologist or primary care doctor if you have worsening symptoms such as heavier or more frequent bleeding, severe abdominal pain, fever, rapid weight loss, or signs of dehydration. If your UC symptoms are interfering with sleep, work, or daily life, it’s reasonable to discuss treatment options and whether a clinical trial might be appropriate.
Disclaimer
This article summarizes research presentations scheduled for UEG Week 2026. It does not provide medical advice. Treatment decisions should be made with your doctor. The conference presentations include company- and investigator-reported findings; conference abstracts and press materials may precede peer-reviewed publication.
Sources
- United European Gastroenterology Week 2026; abstracts and program listing for presentations on obefazimod (ABTECT-Maintenance, ABTECT induction trials, and phase 2 long-term analyses). (Source: United European Gastroenterology Week 2026)